Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VTI-531
- Development stage
- Unknown
- Lead developer
- ViCardia Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
VTI-531 (formerly GP-531) is a clinical-stage, second-generation adenosine-regulating agent (ARA) and AMP-activated protein kinase (AMPK) activator being developed by ViCardia Therapeutics. It is designed to treat mitochondrial metabolic dysfunction in heart failure, specifically targeting Acute Decompensated Heart Failure (ADHF) and Heart Failure with preserved Ejection Fraction (HFpEF). VTI-531 acts as an AMP-mimetic and AICA riboside derivative that stimulates glucose and fatty acid uptake, enhancing mitochondrial energy output (ATP production) and improving cardiac contractile function without causing adverse hemodynamic effects like bradycardia or hypotension. The drug is formulated for intravenous (IV) administration and delivered via the MitoForge precision intracellular delivery platform.
- Other names
- 5-amino-1-beta-D-(5'-benzylamino-5'-deoxyribofuranosyl)imidazole-4-carboxamide5-amino-1-beta-D-(5'-benzylamino-5'-deoxyribofuranosyl)imidazole-4-carboxamide tartrateGP-531 tartrateGP531 tartrateGP 531 tartrate
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)ADOR (Adenosine receptors)
Beyond the preview
Go deeper on VTI-531.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VTI-531.